ReviewPhotodermatology, photoimmunology & photomedicine2025
Modernizing U.S. Sunscreen Regulations: How Newer Filters Can Improve Public Health.
Review in Photodermatology, photoimmunology & photomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Bemotrizinol and the modernization of US sunscreen regulation.JAAD international · 2026Article
- Bemotrizinol: A New Era for US Sunscreens and Pediatric Photoprotection.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Beyond Melanin: A Literature Review of Photoprotection Mechanisms and Gaps in Skin of Color.Cureus · 2026Review
- Thyroid disrupting effects of exposure to sunscreens: in vitro and in vivo evidence of the impact of organic UV-filters.Environmental health : a global access science source · 2025Review
- Modernizing U.S. Sunscreen Regulations: How Newer Filters Can Improve Public Health.Photodermatology, photoimmunology & photomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkin cancer is the most common cancer in the United States, with over 5 million cases diagnosed annually. Despite being largely preventable, incidence rates continue to rise, largely due to inadequate protection from ultraviolet (UV) radiation, the primary environmental cause of skin cancer. Although global innovation has advanced sunscreen technology, the U.S. regulatory system has not kept pace, limiting public access to more effective UV filters.
methodsThis review examines the current U.S. Food and Drug Administration (FDA) sunscreen filter regulatory framework, including the Generally Recognized As Safe and Effective (GRASE) criteria and maximal usage trial (MUsT) protocols. We compare U.S. approved filters with newer filters used internationally and analyze barriers to their domestic approval.
resultsInternational markets currently use advanced filters such as bemotrizinol, bisoctrizole, drometrizole trisiloxane (DT), and terephthalylidene dicamphor sulfonic acid (TDSA), which offer broader and more stable UV protection. These filters have demonstrated favorable safety and efficacy profiles but remain unavailable in the U.S. due to regulatory inertia. The FDA's new Over-the-Counter (OTC) Monograph Order Request (OMOR) process may provide a pathway to modernize sunscreen regulations.
conclusionModernizing U.S. sunscreen regulations to allow approval of newer, evidence-backed UV filters is a critical step in improving public health. Broader access to more effective sunscreens could play a significant role in reducing the incidence of UV-induced skin cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.